Prevention and Treatment of Atherosclerosis: The Use of Nutraceuticals and Functional Foods | SpringerLink
Journal of Cellular Physiology | Cell Biology Journal | Wiley Online Library
Obesity and chronic kidney disease | American Journal of Physiology-Endocrinology and Metabolism
![PDF] The Role and Function of HDL in Patients with Chronic Kidney Disease and the Risk of Cardiovascular Disease | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/deba401d9761b90d6afcfe7d2fe0f0d0f0da448f/3-Figure1-1.png "PDF] The Role and Function of HDL in Patients with Chronic Kidney Disease and the Risk of Cardiovascular Disease | Semantic Scholar")
PDF] The Role and Function of HDL in Patients with Chronic Kidney Disease and the Risk of Cardiovascular Disease | Semantic Scholar
PDF) Markers of increased atherosclerotic risk in patients with chronic kidney disease: A preliminary study
Full article: Elevated soluble LOX-1 predicts risk of first-time myocardial infarction
PDF) Markers of increased cardiovascular risk in patients with chronic kidney disease
Bone-Related Proteins as Markers in Vascular Remodeling | SpringerLink
The Role of Nutraceuticals in Statin Intolerant Patients | Journal of the American College of Cardiology
Circulating CD5L is associated with cardiovascular events and all-cause mortality in individuals with chronic kidney disease | Aging
Deletion of bone marrow myeloperoxidase attenuates chronic kidney disease accelerated atherosclerosis - ScienceDirect
PDF) Impact of Sex Differences and Diabetes on Coronary Atherosclerosis and Ischemic Heart Disease | Salvatore De Rosa - Academia.edu
PDF) Markers of Atherosclerosis in Hypertensive Patients with Less Advanced Chronic Kidney Disease | Claudia Floriana Suciu - Academia.edu
Frontiers | Methods on LDL particle isolation, characterization, and component fractionation for the development of novel specific oxidized LDL status markers for atherosclerotic disease risk assessment
Clinical Update: Cardiovascular Disease in Diabetes Mellitus | Circulation
Frontiers | Inflammation and Cardiovascular Disease Associated With Hemodialysis for End-Stage Renal Disease
IJMS | Free Full-Text | Emerging Anti-Atherosclerotic Therapies
2020 Guidelines of the Polish Society of Laboratory Diagnostics (PSLD) and the Polish Lipid Association (PoLA) on laboratory diagnostics of lipid metabolism disorders
![PDF] Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/b2d8dd1950371360aa5e4be3f1697fcdd27dd8c2/2-Figure1-1.png "PDF] Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies. | Semantic Scholar")
PDF] Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies. | Semantic Scholar
Prevention, diagnosis and treatment of atherosclerosis – Pathology
Lp-PLA2, a new biomarker of vascular disorders in metabolic diseases - Alessandro De Stefano, Liliana Mannucci, Federica Tamburi, Carmine Cardillo, Francesca Schinzari, Valentina Rovella, Steven Nisticò, Luigi Bennardo, Nicola Di Daniele, Manfredi
Cholesterol Metabolism in CKD. - Abstract - Europe PMC
Comparing hs-CRP and MPO Biomarkers of Subclinical Atherosclerosis in Metabolic Syndrome Patients - Journal of Pure and Applied Microbiology
Clinical Update: Cardiovascular Disease in Diabetes Mellitus | Circulation
Frontiers | Methods on LDL particle isolation, characterization, and component fractionation for the development of novel specific oxidized LDL status markers for atherosclerotic disease risk assessment
There is a U shaped association between non high density lipoprotein cholesterol with overall and cardiovascular mortality in chronic kidney disease stage 3–5 | Scientific Reports
